Bellerophon Therapeutics Analysis
| BLPHDelisted Stock | USD 0.71 0.01 1.43% |
Bellerophon Therapeutics is overvalued with Real Value of 0.67 and Hype Value of 0.71. The main objective of Bellerophon Therapeutics pink sheet analysis is to determine its intrinsic value, which is an estimate of what Bellerophon Therapeutics is worth, separate from its market price. There are two main types of Bellerophon Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Bellerophon Therapeutics pink sheet is traded in the USA on PINK Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Bellerophon Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
Bellerophon |
Bellerophon Pink Sheet Analysis Notes
About 45.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.05. Some equities with similar Price to Book (P/B) outperform the market in the long run. Bellerophon Therapeutics recorded a loss per share of 0.34. The entity last dividend was issued on the 10th of February 2020. The firm had 1:15 split on the 10th of February 2020. Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey. Bellerophon Ther operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 20 people.The quote for Bellerophon Therapeutics is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. For more info on Bellerophon Therapeutics please contact the company at 908 574 4770 or go to www.bellerophon.com.Bellerophon Therapeutics Investment Alerts
| Bellerophon Therapeutics is not yet fully synchronised with the market data | |
| Bellerophon Therapeutics has some characteristics of a very speculative penny stock | |
| Bellerophon Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (19.83 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Bellerophon Therapeutics currently holds about 16.33 M in cash with (17.77 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.71, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Bellerophon Therapeutics Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Bellerophon Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 13th of November 2023 Upcoming Quarterly Report | View | |
| 30th of September 2023 Next Fiscal Quarter End | View | |
| 30th of June 2023 Last Quarter Report | View |
Bellerophon Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 1.25 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Bellerophon Therapeutics's market, we take the total number of its shares issued and multiply it by Bellerophon Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Bellerophon Profitablity
The company has Profit Margin (PM) of (2.2) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (2.48) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $2.48.Bellerophon Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bellerophon Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bellerophon Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bellerophon Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Parag Shah over a year ago Acquisition by Parag Shah of 50000 shares of Bellerophon Therapeutics subject to Rule 16b-3 | ||
Parag Shah over a year ago Acquisition by Parag Shah of 50000 shares of Bellerophon Therapeutics subject to Rule 16b-3 |
Bellerophon Therapeutics Outstanding Bonds
Bellerophon Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Bellerophon Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Bellerophon bonds can be classified according to their maturity, which is the date when Bellerophon Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
About Bellerophon Pink Sheet Analysis
Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how Bellerophon Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Bellerophon shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as Bellerophon Therapeutics. By using and applying Bellerophon Pink Sheet analysis, traders can create a robust methodology for identifying Bellerophon entry and exit points for their positions.
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey. Bellerophon Ther operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 20 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our pink sheet analysis tools, you can find out how much better you can do when adding Bellerophon Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Equity Search Now
Equity SearchSearch for actively traded equities including funds and ETFs from over 30 global markets |
| All Next | Launch Module |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Other Consideration for investing in Bellerophon Pink Sheet
If you are still planning to invest in Bellerophon Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bellerophon Therapeutics' history and understand the potential risks before investing.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |